Dane Leone

Mr. Leone guides Xencor’s strategy to achieve corporate goals by supporting the Company’s R&D and clinical leadership, overseeing assessment and prioritization of current and future XmAb® drug programs and overseeing business development and investor relations activities. Mr. Leone most recently was leading equity research analyst, serving as a managing director and senior biotechnology analyst at Raymond James. Mr. Leone’s focus areas in equity research included oncology, immunology, cardiology and ophthalmology. His coverage spanned securities across a wide range of market capitalization, from biotechnology companies advancing a diverse set of drug candidates to commercializing novel medicines. Before Raymond James, Mr. Leone held analyst roles with increasing seniority at BTIG and Macquarie Securities Group. He began his career in portfolio management as a health care and quantitative research analyst at AllianceBernstein. Mr. Leone received his B.S. in business from the State University of New York at Albany. He holds the Chartered Financial Analyst® designation from the CFA® Institute.

CFA® and Chartered Financial Analyst® are registered trademarks of CFA Institute.